First Horizon Advisors Inc. Buys 475 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

First Horizon Advisors Inc. boosted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 103.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 932 shares of the medical equipment provider’s stock after acquiring an additional 475 shares during the quarter. First Horizon Advisors Inc.’s holdings in Lantheus were worth $58,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Tucker Asset Management LLC lifted its stake in Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares during the last quarter. Covestor Ltd boosted its holdings in Lantheus by 62.7% during the 3rd quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 203 shares during the period. Parkside Financial Bank & Trust grew its position in Lantheus by 36.6% in the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 156 shares during the last quarter. NBC Securities Inc. purchased a new stake in Lantheus in the third quarter worth $46,000. Finally, Ulland Investment Advisors LLC bought a new stake in shares of Lantheus during the fourth quarter worth $135,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LNTH has been the topic of several recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $100.00 price target on shares of Lantheus in a research note on Friday, February 23rd. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Truist Financial boosted their price target on Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a report on Friday, May 3rd. Mizuho lifted their target price on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. Finally, B. Riley increased their price target on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $99.17.

Lantheus Trading Up 0.7 %

Shares of NASDAQ:LNTH opened at $76.01 on Wednesday. The company has a current ratio of 4.84, a quick ratio of 4.55 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $5.27 billion, a PE ratio of 11.60 and a beta of 0.52. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $100.85. The business’s fifty day simple moving average is $62.97 and its 200-day simple moving average is $62.80.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.26. The company had revenue of $354.00 million for the quarter, compared to analyst estimates of $350.44 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 5.96 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were acquired at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the acquisition, the insider now owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was bought at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the purchase, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the sale, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Insiders sold 94,545 shares of company stock valued at $6,169,936 over the last 90 days. Insiders own 2.10% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.